FDA Limits Use of J & J COVID-19 Vaccine Due to Blood Clot Risk
FRIDAY, May 6, 2022 -- Citing the accumulated data on a raised risk for thrombosis with thrombocytopenia syndrome (TTS), the U.S. Food and Drug Administration on Thursday greatly restricted the recommended use of the Johnson& Johnson COVID-19... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - May 6, 2022 Category: Pharmaceuticals Source Type: news
FDA Puts Strict Limits On Johnson & Johnson COVID Vaccine
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - May 6, 2022 Category: Consumer Health News Authors: Health – CBS Boston Tags: COVID-19 Health News CNN Coronavirus Johnson & Johnson Vaccine Source Type: news
Johnson & Johnson Updates U.S. COVID-19 Vaccine Fact Sheet
NEW BRUNSWICK, NJ, May 5, 2022 - Our number one priority is the safety and well-being of those who use the Johnson & Johnson COVID-19 vaccine. Johnson & Johnson, in close coordination with the U.S. Food and Drug Administration (FDA), has updated its U.S. COVID-19 Vaccine Fact Sheet to increase awareness about the risk of thrombosis with thrombocytopenia syndrome (TTS), a rare but potentially life-threatening condition. Language about the risk of TTS has been added to the first page of the Fact Sheet to increase its prominence. Following the update to the Fact Sheet, the Johnson & Johnson COVID-19 vaccine is now...
Source: Johnson and Johnson - May 5, 2022 Category: Pharmaceuticals Source Type: news
FDA Severely Limits Use of J & J COVID Shot
(MedPage Today) -- Use of Johnson and Johnson's (J&J) COVID-19 vaccine should only be limited to certain adults, the FDA said on Thursday. Due to an updated analysis of the rare cases of thrombosis with thrombocytopenia syndrome (TTS), which... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - May 5, 2022 Category: American Health Source Type: news
What is in the Differential Diagnosis for Green, Blue or Violet Skin Conditions?
Discussion Acrocyanosis is commonly seen in the newborn period as the baby transitions to extra-uterine life. It appears as blue-purple coloration of the distal extremities which usually improves over several hours. Blue melanocytosis is also a common normal variant of skin color. It usually is seen on the posterior surface of the body around the spine and buttocks, but can also be on the upper parts of the extremities. It is a blue-black coloration that shows a normal skin undertone when palpated. This is the second in a short case series of differential diagnoses of colored skin conditions. An introduction to dermatologi...
Source: PediatricEducation.org - May 2, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
BTK Inhibitor Shows Potential in Immune Thrombocytopenia
(MedPage Today) -- An investigational oral Bruton's tyrosine kinase (BTK) inhibitor was tolerable and yielded rapid and durable responses in pretreated patients with immune thrombocytopenia (ITP), according to results of an open-label phase I/II... (Source: MedPage Today Hematology/Oncology)
Source: MedPage Today Hematology/Oncology - April 13, 2022 Category: Hematology Source Type: news
Physicians Assess Cardiovascular Safety of COVID-19 Vaccines Physicians Assess Cardiovascular Safety of COVID-19 Vaccines
After a review of the data, the Brazilian Society of Cardiology concluded that the benefits of vaccination outweigh the potential risks of thrombotic thrombocytopenia and myocarditis.Medscape Medical News (Source: Medscape Cardiology Headlines)
Source: Medscape Cardiology Headlines - April 11, 2022 Category: Cardiology Tags: Infectious Diseases News Source Type: news
Statins side effects: Drug can cause thrombocytopenia warns the NHS - signs on your body
STATINS provide a bulwark against heart disease by lowering harmful cholesterol levels. However, the cholesterol-lowering drug can cause side effects, including thrombocytopenia - what are the signs on your body? (Source: Daily Express - Health)
Source: Daily Express - Health - March 24, 2022 Category: Consumer Health News Source Type: news
Risk for Blood Clots After COVID - 19 Vaccination Explored
Two studies show increase in intracranial venous thrombosis, thrombocytopenia for those younger than 70 years and in CVST after ChAdOx1 - S (Source: The Doctors Lounge - Oncology)
Source: The Doctors Lounge - Oncology - March 11, 2022 Category: Cancer & Oncology Tags: Family Medicine, Infections, Internal Medicine, Oncology, Pharmacy, Journal, Source Type: news
Risk for Blood Clots After COVID-19 Vaccination Explored
FRIDAY, March 11, 2022 -- There is a small increased risk for intracranial venous thrombosis, thrombocytopenia, and cerebral venous sinus thrombosis (CVST) after the ChAdOx1-S COVID-19 vaccination, but not after the BNT162b2 vaccination, according... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - March 11, 2022 Category: Pharmaceuticals Source Type: news
FDA Approves First Drug for Myelofibrosis With Thrombocytopenia FDA Approves First Drug for Myelofibrosis With Thrombocytopenia
Pacritinib is indicated specifically for patients with myelofibrosis and very low platelet counts, which develop in about one third of patients.FDA Approvals (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - March 1, 2022 Category: Consumer Health News Tags: Hematology-Oncology News Source Type: news
U.S. FDA Approves CARVYKTI ™ (ciltacabtagene autoleucel), Janssen’s First Cell Therapy, a BCMA-Directed CAR-T Immunotherapy for the Treatment of Patients with Relapsed or Refractory Multiple Myeloma
HORSHAM, Pa., February 28, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson announced today the U.S. Food and Drug Administration (FDA) has approved CARVYKTI™ (ciltacabtagene autoleucel; cilta-cel) for the treatment of adults with relapsed or refractory multiple myeloma (RRMM) after four or more prior lines of therapy, including a proteasome inhibitor, an immunomodulatory agent, and an anti-CD38 monoclonal antibody.1 The approval is based on data from the pivotal CARTITUDE-1 study, which included patients who had received a median of six prior treatment regimens (range, 3-18), and had previously rec...
Source: Johnson and Johnson - March 1, 2022 Category: Pharmaceuticals Tags: Innovation Source Type: news
FDA Approves Vonjo (pacritinib) for the Treatment of Adult Patients with Myelofibrosis and Thrombocytopenia
SEATTLE, Feb. 28, 2022 /PRNewswire/ -- CTI BioPharma Corp. (Nasdaq: CTIC) today announced the U.S. Food and Drug Administration (FDA) has approved Vonjo (pacritinib) for the treatment of adults with intermediate or high-risk primary or secondary... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - February 28, 2022 Category: Drugs & Pharmacology Source Type: news
When Can Menstrual Suppression Start in Patients with a Disability?
Discussion Menstrual suppression using hormonal therapy is commonly used for a variety of reasons: Patient preference Contraception Heavy or painful menses Treatment of concomitant problems such as menstrual migraine, mood issues, nausea Specific patient populations Disabilities Oncology Transgender and gender nonbinary Methods of suppression include: Estrogen and progesterone Combined oral contraceptives (COC) – very good menstrual suppression and generally used as first line treatment for many patients Traditional dosing with active medication for 21-24 days and then 4-7 day placebo break. Extended cycles &...
Source: PediatricEducation.org - February 14, 2022 Category: Pediatrics Authors: Pediatric Education Tags: Uncategorized Source Type: news
A Male Infant with Cholestatic Jaundice, Hemolytic Anemia, and Thrombocytopenia
(Source: NeoReviews recent issues)
Source: NeoReviews recent issues - February 1, 2022 Category: Pediatrics Source Type: news